Cash of €1.9 million (excluding CIR) as of June 30, 2023
Toulouse, FRANCE, Lakeland, USA, August 17, 2023, 5:45 p.m. – ABIONYX Pharma (FR0012616852 – ABNX), a next-generation biotech company dedicated to the discovery and development of innovative therapies, today reports its cash position for the 1st six months ended June 30, 2023 and the highlights of the period.
The company recorded consolidated half-year revenue of €2.1 million, after elimination of intra-group transactions. IRIS Pharma recorded half-year sales of €2.4 million.
As of June 30, 2023, ABIONYX Pharma’s cash position stood at €1.9 million before receipt of CIRs from ABIONYX Pharma and IRIS Pharma.
Since the beginning of the year, the company has successfully produced two first batches for the industrial bioproduction under GMP (Good Manufacturing Practices) of CER-001 using an innovative and robust method. ABIONYX thus confirms its ability to produce batches using the new production line linked to an innovative and efficient approach based on the recombinant ApoA-I protein.